Literature DB >> 27590778

[Candiduria! What now? : Therapy of urinary tract infections with Candida].

H Hof1.   

Abstract

BACKGROUND: Yeasts are found in urine specimens relatively often, especially in the elderly and patients under treatment with broad spectrum antibiotics, i. e. especially in intensive care unit (ICU) patients. In some cases, the number of pathogens is very high, i. e. >105/ml. The clinical relevance of detecting Candida in urine is difficult to assess. In the German S3 guidelines it is apodictically stated that an ascending infection of the urinary tract by yeasts does not occur but this may undoubtedly happen in certain instances in patients at risk, for example in the elderly, in diabetic persons and in the case of foreign bodies in the urinary tract. A hematogenous spread of yeasts can lead to pyelonephritis, which accompanies candiduria. In rare cases this can be induced by prostatitis and epididymitis. Therapy is indicated in all cases when a urological manipulation is planned, particularly those with injury to the mucosal barrier, in order to prevent an intraoperative spread of pathogens. AIM: The antimicrobial agents suitable for therapy of candiduria are limited, namely flucytosine, amphotericin B, which is also used for irrigation and fluconazole.
MATERIAL AND METHODS: The in vitro effect of nitroxoline on 100 isolates of yeasts from urine was tested by an agar diffusion test.
RESULTS: Nitroxoline exerted a good activity against all yeast isolates. DISCUSSION: The antibiotic nitroxoline has a good antifungal activity. It achieves high concentrations in urine and in addition, it is effective at low pH as well as against pathogens in biofilms, which most antimycotics cannot achieve. Hence, nitroxoline is suitable for termination of candiduria. Foreign bodies in the urinary tract, on which biofilms are formed, should be removed whenever possible.

Entities:  

Keywords:  Amphotericin B; Broad spectrum antibiotics; Fluconazole; Flucytosin; Nitroxoline

Mesh:

Substances:

Year:  2017        PMID: 27590778     DOI: 10.1007/s00120-016-0219-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  37 in total

1.  Candida urinary tract infections--treatment.

Authors:  John F Fisher; Jack D Sobel; Carol A Kauffman; Cheryl A Newman
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

2.  The value of a single amphotericin B bladder washout in candiduria.

Authors:  I W Fong
Journal:  J Antimicrob Chemother       Date:  1995-12       Impact factor: 5.790

Review 3.  Pharmacokinetic evaluation of fluconazole in critically ill patients.

Authors:  Mahipal Sinnollareddy; Sandra L Peake; Michael S Roberts; E Geoffrey Playford; Jeffrey Lipman; Jason A Roberts
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-09-02       Impact factor: 4.481

4.  Comparison Between Virulence Factors of Candida albicans and Non-Albicans Species of Candida Isolated from Genitourinary Tract.

Authors:  Shani Jacob; Diney D'Souza
Journal:  J Clin Diagn Res       Date:  2014-11-20

5.  Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates.

Authors:  D T A te Dorsthorst; P E Verweij; J F G M Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 6.  Candida urinary tract infections: treatment options.

Authors:  Anurag N Malani; Carol A Kauffman
Journal:  Expert Rev Anti Infect Ther       Date:  2007-04       Impact factor: 5.091

7.  Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.

Authors:  Claire S Danby; Dina Boikov; Rina Rautemaa-Richardson; Jack D Sobel
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

8.  Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers.

Authors:  Florian M E Wagenlehner; Fabian Münch; Adrian Pilatz; Birte Bärmann; Wolfgang Weidner; Christine M Wagenlehner; Marion Straubinger; Holger Blenk; Wolfgang Pfister; Michael Kresken; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

10.  Diagnosis and inflammatory response of patients with candiduria.

Authors:  S Helbig; J M Achkar; N Jain; X Wang; P Gialanella; M Levi; B C Fries
Journal:  Mycoses       Date:  2012-05-10       Impact factor: 4.377

View more
  4 in total

Review 1.  Innate Bacteriostatic Mechanisms Defend the Urinary Tract.

Authors:  Jose A Munoz; Anne-Catrin Uhlemann; Jonathan Barasch
Journal:  Annu Rev Physiol       Date:  2021-11-15       Impact factor: 22.163

2.  Nitroxoline: an option for the treatment of urinary tract infection with multi-resistant uropathogenic bacteria.

Authors:  Herbert Hof; C Juretschke
Journal:  Infection       Date:  2018-11-17       Impact factor: 3.553

Review 3.  UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies.

Authors:  Maria E Terlizzi; Giorgio Gribaudo; Massimo E Maffei
Journal:  Front Microbiol       Date:  2017-08-15       Impact factor: 5.640

Review 4.  Antibiotic Resistance Among Uropathogenic Escherichia coli.

Authors:  Barbara Kot
Journal:  Pol J Microbiol       Date:  2019-12-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.